Rangeley Capital »

Inhibikase Therapeutics shares owned by Rangeley Capital

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Rangeley Capital from 13F filings

Historical chart of Rangeley Capital investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Rangeley Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Rangeley Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $370k 220k 1.68

More positions owned by Rangeley Capital

Liquidia Corporation Com New Put Option (LQDA)
Driven Brands Hldgs (DRVN)
Revolution Medicines (RVMD)
Prothena Corp SHS (PRTA)
Seaport Entmt Group Common Stock (SEG)
Warner Bros Discovery Com Ser A (WBD)
Grindr (GRND)
Delek Us Holdings (DK)
Arvinas Ord (ARVN)
Arbutus Biopharma (ABUS)
Echostar Corp Cl A (SATS)
Leggett & Platt (LEG)
Star Hldgs Shs Ben Int (STHO)
Full House Resorts (FLL)
Tripadvisor (TRIP)

View all positions for Rangeley Capital

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
Trails Edge Capital Partners
ADAR1 Capital Management
BlackRock
Blackstone Group
Siren
Commodore Capital
Vanguard Group
Vanguard Capital Management
Saturn V Capital Management
Kalehua Capital Management
Squadron Capital Management
Millennium Management

View all funds holding Inhibikase Therapeutics